Femasys Inc. reported financial results for the quarter ended June 30, 2026, alongside a corporate update highlighting key strategic milestones. The company completed a $30 million private placement with potential proceeds of up to $90 million upon full warrant exercise, which management states provides capital to execute its U.S. commercial strategy and advance clinical programs. Femasys regained compliance with Nasdaq listing requirements and appointed John Canning as Chief Operating Officer. For the quarter ended June 30, sales decreased 18.9% to $331,827 from $409,268 in the prior year period, while R&D expenses increased 37.6% to $1,946,878 due to higher clinical costs and inventory transitions. The net loss for the quarter was $4,469,095, or ($1.33) per share, compared to a net loss of $4,585,922 in the same period last year. Cash and cash equivalents stood at approximately $1.4 million as of June 30, 2026. Femasys Inc. is a biomedical innovator developing fertility treatments and non-surgical permanent birth control solutions.

Femasys Inc. entered into a private placement agreement on August 7, 2026, closing on August 10, 2026, to raise approximately $30 million in gross proceeds. The company issued 5,013,559 shares of common stock at $3.20 per share and pre-funded warrants for 4,361,440 additional shares at $3.1999 each. Accompanying these instruments were two warrant series totaling 18,749,998 shares: Common Warrants exercisable immediately at $2.95 per share, and Milestone Warrants exercisable upon achieving specific revenue and stock price targets, also at $2.95 per share. Five executives participated in the offering, purchasing approximately $134,000 of securities on identical terms. Additionally, Nantahala Capital Management LLC terminated its rights to designate board members and observers under a prior convertible note agreement. Femasys Inc. operates in the medical device industry, developing minimally invasive treatments for pelvic organ prolapse.

Femasys Inc. received written notice from Nasdaq regarding its regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company regained compliance following a 1-for-20 reverse stock split effective June 5, 2026, which brought the closing bid price above $1.00 per share. Femasys Inc. operates in the medical technology industry and develops surgical-robotic and surgical-robotic-assisted technology solutions.